- Guide to PHARMACOLOGY
Synonyms: BMS 777607 | BMS777607
Compound class: Synthetic organic
Comment: BMS-777607is a selective and orally bioavailable MET tyrosine kinase (hepatocyte growth factor receptor) inhibitor with potential antineoplastic activity. Its discovery is described by Schroeder et al. (2009)  where it is compound 10. It also has significant activity against other receptor tyrosine kinases, with details presented in the Biological activity tab..
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.
|Summary of Clinical Use
|A single Phase 2 clinical trial for advanced or metastatic solid tumors (NCT00605618) has been completed. Development has not progressed beyond Phase 2.
|Mechanism Of Action and Pharmacodynamic Effects
|Inhibition of hepatocyte growth factor (HGF) binding to c-MET disrupts the MET signaling pathway and this may induce cell death in tumour cells driven by c-MET.